TELA Bio director buys 75,000 shares around $1

A TELA Bio director purchased 75,000 shares of company stock in open-market transactions at just over $1 per share.

Rhea-AI Filing Summary

TELA Bio, Inc. (TELA) director Joseph H. Capper reported open-market purchases of the company’s common stock on two consecutive days in September 2026. On September 14, 2026 he bought 25,000 shares at a weighted average price of $1.0201 per share in multiple trades priced between $0.9899 and $1.04. On September 15, 2026 he bought an additional 50,000 shares at a weighted average price of $1.0588 per share in multiple trades priced between $1.01 and $1.10. In total, Capper purchased 75,000 shares of TELA Bio common stock in these transactions, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Buyer: 75,000 shares

Net Buy 2 txns

Insider Capper Joseph H

Role Director

Bought 75,000 shs ($78K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F2	50,000	$1.0588	$53K
Purchase	Common Stock F1	25,000	$1.0201	$26K

Holdings After Transaction: Common Stock — 104,827 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9899 to $1.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.01 to $1.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares purchased September 14, 2026: 25,000 shares Weighted average price September 14, 2026: $1.0201 per share Price range September 14, 2026: $0.9899–$1.04 per share +4 more

7 metrics

Shares purchased September 14, 2026 25,000 shares Open-market purchase of TELA Bio common stock by director

Weighted average price September 14, 2026 $1.0201 per share Purchases executed in multiple trades between $0.9899 and $1.04

Price range September 14, 2026 $0.9899–$1.04 per share Range of prices for the 25,000 shares purchased

Shares purchased September 15, 2026 50,000 shares Open-market purchase of TELA Bio common stock by director

Weighted average price September 15, 2026 $1.0588 per share Purchases executed in multiple trades between $1.01 and $1.10

Price range September 15, 2026 $1.01–$1.10 per share Range of prices for the 50,000 shares purchased

Total shares purchased 75,000 shares Combined insider purchases on September 14–15, 2026

Key Terms

weighted average price, open market or private transaction, Rule 10b5-1 trading plan

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"Purchase in open market or private transaction"

Rule 10b5-1 trading plan regulatory

"no Rule 10b5-1 trading plan is reported for the transactions"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider buying did TELA (TELA) disclose in this Form 4?

TELA Bio disclosed that director Joseph H. Capper bought a total of 75,000 shares of common stock in open-market transactions on September 14–15, 2026 at weighted average prices slightly above $1 per share.

How many TELA (TELA) shares did Joseph H. Capper buy on each date?

On September 14, 2026, Joseph H. Capper bought 25,000 shares of TELA Bio common stock. On September 15, 2026, he bought an additional 50,000 shares, for a combined total of 75,000 shares reported in this filing.

At what prices were the TELA (TELA) insider share purchases made?

On September 14, 2026, shares were bought at a weighted average price of $1.0201, across trades from $0.9899 to $1.04. On September 15, 2026, the weighted average price was $1.0588, with trades from $1.01 to $1.10.

Were Joseph H. Capper’s TELA (TELA) stock purchases under a Rule 10b5-1 plan?

No. The Form 4 indicates that no Rule 10b5-1 trading plan is reported for the transactions disclosed, meaning the purchases are not identified as being made under a pre-arranged trading plan.

What type of transactions did the TELA (TELA) Form 4 report?

The Form 4 reports open-market or private purchase transactions of TELA Bio common stock by director Joseph H. Capper, coded as “P” transactions in the filing, reflecting acquisitions rather than sales.

Did the Form 4 state how many TELA (TELA) shares Joseph H. Capper owns after these purchases?

No. For each reported transaction, the field for total shares held following the transaction is left blank, so the filing does not state Joseph H. Capper’s overall TELA Bio share holdings after these purchases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 06:47 PM Accepted by SEC EDGAR 09/16/2026 - 06:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Capper Joseph H

(Last) (First) (Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/14/2026		P		25,000	A	$1.0201(1)	54,827	D
Common Stock	09/15/2026		P		50,000	A	$1.0588(2)	104,827	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9899 to $1.04. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.01 to $1.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Megan Smeykal, Attorney-in-Fact	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)